335 results about "Nicotinamide mononucleotide" patented technology

The invention discloses application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products, wherein nicotinamide mononucleotide is applied to preparation of anti-aging drugs or health products. The nicotinamide mononucleotide (NMN) provided by the invention is used as an active ingredient in preparation of anti-aging drugs or health products. The specific dose can be decided according to the severity degree of diseases, drug delivery approaches and related factors. NMN itself is a body intracellular substance, has high safety as a drug or health product, and the NMN is a monomer molecule, the efficacy is obvious and stable.

The invention discloses the application of nicotinamide mononucleotide on preparing medicines or health-care food for resisting neuronal cell injury cerebral apoplexy or oxygen-glucose deprivation. The invention also provides a novel medical composite which can effectively resist the neuronal cell injury caused by cerebral apoplexy and oxygen-glucose deprivation, thereby showing great significance to the treatment of cerebral apoplexy; and the active component in the medical composite is the nicotinamide mononucleotide which is an endogenic protective substance for an organic body and can not generate side effects according to current information, and therefore the nicotinamide mononucleotide used as a medicine has higher security and wide time window for treatment.

The invention belongs to the field of chemical synthesis, and particularly relates to a method for preparing beta-niacinamide single nucleotide or beta-niacinamide ribose, which aims at solving the technical problem of providing a method for preparing beta-niacinamide single nucleotide or beta-niacinamide ribose. The method comprises the following steps of performing condensation, deacetylation, phosphorylation and ammonolysis on ethyl niacinate and tetraacetyl ribose, so as to obtain the beta-niacinamide single nucleotide; performing condensation, deacetylation, and ammonolysis on ethyl niacinate and tetraacetyl ribose, so as to obtain the beta-niacinamide ribose. Compared with the conventional methods, the method has the advantages that the operation is simple, the amplification is easy,the purification is easy, the yield rate is high, and the like.

The invention discloses an NAD analogue as well as the synthesis and the application thereof. The structural formula I of the NAD analogue is a di-phosphate ester compound generated by reacting nicotinamide mononucleotide and corresponding alcohol. An R is a C4-C15 saturated or unsaturated alkyl or saturated or unsaturated alkyl A containing C2-C10 of a heteroatom; and (the R details as the formula II). The NAD analogue can promote the growth of the microorganisms such as colibacillus, saccharomyces cerevisiae, and the like; and the NAD analogue can be also taken as the dehydrogenase cofactor used for catalytic oxidation and reduction reaction.

The invention relates to a preparation method of nicotinamide adenine dinucleotide, which comprises the following steps of: with 1,2,3,5-tetraacetyl-beta-D-ribofuranose as a starting raw material, preparing nicotinamide mononucleotide through sequentially a condensation reaction, an ammonolysis reaction and a phosphorylation reaction; and then mixing the prepared nicotinamide mononucleotide with adenosine triphosphate, generating an enzymic catalytic reaction in the presence of nicotinamide adenosine nucleotide transferase and pyrophosphatase to prepare the nicotinamide adenine dinucleotide. Compared with the prior art, the technical scheme provided by the invention has the advantage that the whole process is simplified and optimized by combination of a chemical method and an enzymic method.

The invention discloses the application of nicotinamide mononucleotide on preparing medicines or health-care food for resisting neuronal cell injury cerebral apoplexy or oxygen-glucose deprivation. The invention also provides a novel medical composite which can effectively resist the neuronal cell injury caused by cerebral apoplexy and oxygen-glucose deprivation, thereby showing great significance to the treatment of cerebral apoplexy; and the active component in the medical composite is the nicotinamide mononucleotide which is an endogenic protective substance for an organic body and can notgenerate side effects according to current information, and therefore the nicotinamide mononucleotide used as a medicine has higher security and wide time window for treatment.

The invention belongs to the fields of research and development of drugs and health-care products, particularly relates to an application of a nicotinamide mononucleotide containing composition to ageing resisting drugs / health-care products, provides a composition, further provides a preparation method of the composition, and further provides the composition or the application of the product prepared by the preparation method to ageing resisting drugs / health-care products. NMN can achieve the effects of activating organism energy metabolism and improving an organism oxidation stress reaction, and besides, through cooperation with synergism of other components, favorable effect of resisting ageing can be achieved; and the components in the composition are stable in structure. The prepared product is not liable to deteriorate or damage, and besides, the components are safe. The product basically has no poor reaction on human bodies. The composition solves the technical problems that in the prior art, the ageing resisting products do not have favorable ageing resisting effect, are free from damage to human bodies, and are stable in product quality.

The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by biocatalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN.

The invention discloses a composition for improving skin color and a whitening cosmetic. The composition comprises tranexamic acid, acetyl chitosamine and beta-nicotinamide mononucleotide. The tranexamic acid, the acetyl chitosamine and the beta-nicotinamide mononucleotide are compounded, the beta-nicotinamide mononucleotide is combined with the tranexamic acid and the acetyl chitosamine, pigmentation caused by ultraviolet rays or other skin irritation can be inhibited, and skin pigmented spots related to pigmentation are effectively prevented or improved. The acetyl chitosamine can improve transdermal absorption of effective components such as the tranexamic acid and the beta-nicotinamide mononucleotide, has a whitening effect, and can achieve a synergistic whitening effect when being used together with the tranexamic acid and the beta-nicotinamide mononucleotide, so that the tranexamic acid, the acetyl chitosamine and the beta-nicotinamide mononucleotide can achieve whitening and brightening effects at a low concentration, and are stable, safe and non-irritant.

The invention belongs to the field of chemical synthesis, and in particular, relates to a method for preparing beta-niacinamide mononucleotide and an application thereof. The preparation method comprises the steps: S1, condensation reaction: carrying out condensation reaction of ethyl nicotinate, tetraacetylribose and a catalyst in a first solvent to obtain a solution containing ethyl nicotinate triacetylnucleoside; S2, ammonolysis reaction: carrying out ammonolysis reaction of the solution containing ethyl nicotinate triacetylnucleoside through an ammonia gas solution to obtain niacinamide riboside hydrochloride; and S3, phosphorylation reaction: carrying out reaction of niacinamide riboside hydrochloride with phosphorus oxychloride in a second solvent to obtain beta-niacinamide mononucleotide. Compared with a conventional method, the preparation method has the advantages of simple operation, easy amplification, easy purification, high yield and the like.

The invention discloses a biopolymer nanosphere containing nicotinamide mononucleotide (NMN). The biopolymer nanosphere comprises a biopolymer carrier and NMN dispersed on the biopolymer carrier. Thebiopolymer carrier is made of a polymer fiber aggregate, fibrous skeletons of the polymer fiber aggregate constitute a three-dimensional interpenetrating network structure through arrangement modes ofunordered arrangement, cross arrangement, curling arrangement and the like, thus the NMN is protected, the problem that the NMN is prone to being decomposed after encountering light or being oxidizedis solved, the preservation time of effective components of the NMN is prolonged, and the preservation difficulty of the effective components of the NMN is lowered. The invention further discloses apreparation process of the nanosphere, a biopolymer material with the moderate chain length is obtained after physical modification, spherical particles are easy to form, the cellular three-dimensional interpenetrating network structure is constituted, and NMN small molecules are loaded on the inner surface and the outer surface of the network structure advantageously. The nanosphere can be used for preparing preparations such as tablets, particles, capsules or soft capsules and serves as human body health protection or pet therapy drug / functional food.

The present invention discloses a method for purifying β-nicotinamide mononucleotide, comprising the steps of: a. sequentially microfiltrating and nanofiltrating a pretreated β-nicotinamide mononucleotide solution with membrane concentration devices, to collect a concentrated crude product solution; b. adjusting the obtained crude product solution to pH 3-7, loading it onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and ethanol as a mobile phase B, to obtain a purified sample solution; and c. nanofiltrating the purified sample solution with a membrane concentration device, and freeze drying it in a vacuum freeze drier, to obtain purified β-nicotinamide mononucleotide.